Lieske, John C.

Key Points Fibroblast growth factor 23 and 24,25-dihydroxyvitamin D are positively correlated and are significantly lower in Dent disease than in idiopathic calcium kidney stones patients. Dent patients with low 24,25-dihydroxyvitamin D had greater hypercalciuria and proteinuria, and, among adults, higher 1,25-dihydroxyvitamin D concentrations. Moderate phosphate supplementation mitigates hypercalciuria. Background Hypercalciuria is a prominent characteristic in Dent disease type 1 (DD1) and is associated with kidney stones and nephrocalcinosis. The objectives of this study were to assess fibroblast growth factor 23 (FGF23) and 24,25-dihydroxyvitamin D (24,25(OH) 2 D) in DD1 patients and investigate the effects of phosphate supplementation on urinary calcium excretion. Methods Serum and 24-hour urine assessments from adult and pediatric DD1 patients ( N =10 adults; N =9 pediatrics) were compared with adult control subjects with a history of idiopathic calcium kidney stones and hypercalciuria ( N =9). Adult DD1 patients and control participants completed an oral phosphate supplementation intervention (1 g/d×14 days) with reassessment immediately after intervention. Results FGF23 was significantly lower in DD1 than in the control cohort (adults, P = 0.006) and positively correlated with 24,25(OH) 2 D across all study cohorts. The concentrations of 24,25(OH) 2 D were low with conversion ratios (25-hydroxyvitamin D: 24,25(OH) 2 D) exceeding the clinical reference limit for five of 10 adults and six of 9 pediatric DD1 patients. The DD1 cohorts were then stratified by the 24,25(OH) 2 D ratio into “normal” and “low” 24,25(OH) 2 D. Adult DD1 patients with low 24,25(OH) 2 D ( n =5) had lower FGF23, higher 1,25-dihydroxyvitamin D, greater urine calcium, and greater urine protein. Pediatric stratified data mirrored that in adults with the exception of no difference in serum 1,25-dihydroxyvitamin D. Phosphate supplementation was effective in decreasing urine calcium in both adult DD1 and control adult cohorts. Conclusions Clinical measurement of 24,25(OH) 2 D is a novel and useful analysis for evaluating the severity of calcium and protein dysregulation in DD1. In addition, moderate phosphate supplementation effectively mitigates urine calcium excretion in DD1 adult patients. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT02016235.

The glomerular filtration rate (GFR) is a key indicator of kidney function, yet no ideal method exists for its direct measurement. This two-part review examines the development of GFR measurement techniques, focusing on their physiologic basis, performance characteristics, and clinical applications. Part 1 reviews endogenous markers used to estimate GFR (eGFR), including creatinine- and cystatin C-based equations, with emphasis on their derivation, limitations, and clinical use. Part 2 addresses exogenous filtration markers and measured GFR (mGFR) methodologies, highlighting comparative performance and specific uses. Emphasis is placed on innovation in marker development, highlighting the need for continued development and standardization to enhance accuracy and clinical utility.

Measured glomerular filtration rate (mGFR) remains the reference standard for precise assessment of kidney function when estimated approaches are insufficient. This second part of a two-part series reviews exogenous filtration markers used to obtain mGFR, including inulin, iothalamate, iohexol, and radionuclide-based tracers, with emphasis on their physiologic handling, analytic methods, accuracy, and clinical applicability. The review further examines emerging fluorescent and near-infrared tracers coupled with transcutaneous monitoring technologies that enable rapid or continuous assessment of GFR. Together, these approaches illustrate the evolution of mGFR measurement toward methods that are more practical, scalable, and responsive to dynamic changes in kidney function, while maintaining analytical accuracy.

ABSTRACT Background Although kidney biopsy remains the gold standard for diagnosing immune checkpoint inhibitors–associated acute interstitial nephritis (ICI-AIN), several promising urinary biomarkers have emerged as potential non-invasive diagnostics. Notably, recent studies have highlighted tumor necrosis factor alpha (TNF-α), CXC motif chemokine ligand 9 (CXCL-9) and others as potential biomarkers to help distinguish ICI-AIN from other causes of acute kidney injury (AKI). However, a direct systematic comparison between these two biomarkers in a cohort of patients undergoing immunotherapy has not been performed. Methods We prospectively enrolled a cohort of ICI-treated cancer patients who developed AKI (including both ICI-AIN and ICI-Non-AIN AKI), as well as those without AKI, referred to as the internal validation cohort. Urinary CXCL-9 and TNF-α were measured across all groups using the human Quantikine ELISA Kit. We externally validated our findings in a cohort of biopsy proven ICI-AIN patients from Spain, referred to as the external validation cohort. Results Urinary CXCL-9 levels were significantly higher in ICI-AIN patients from Mayo (n = 40) compared with those with ICI-Non-AIN AKI (n = 36) and ICI-treated patients without AKI (n = 16) (both P ≤ .0001); these findings were confirmed in the validation cohort from Spain (n = 19) with P-values of .0008 and <.0001, respectively. The area under the curve (AUC) for urinary CXCL-9 distinguishing ICI-AIN biopsy proven (combined from both cohorts, n = 45) from ICI-Non-AIN AKI was 0.83 (95% confidence interval 0.74–0.92), while for urinary TNF-α the AUC was 0.63 (0.51–0.75). Conclusions Increased urinary CXCL-9 was superior to TNF-α as a biomarker for the non-invasive diagnosis of ICI-AIN, even after prior corticosteroid exposure, highlighting its promise as clinical diagnostic tool.

Key Points Primary hyperoxaluria type 1 is a genetic disorder associated with hepatic oxalate overproduction, kidney failure, and systemic oxalosis. Lumasiran treatment for up to 60 months was associated with sustained reductions in urinary and plasma oxalate and encouraging clinical outcomes. Lumasiran's safety profile was acceptable with mild injection site reactions being the most common adverse events. Background Primary hyperoxaluria type 1 (PH1) is characterized by hepatic oxalate overproduction, kidney stones, and progressive kidney disease. Lumasiran is the first approved treatment for PH1. Methods ILLUMINATE-A (NCT03681184) was a 60-month pivotal, phase 3, multinational clinical trial of lumasiran which consisted of a 6-month double-blind, placebo-controlled period (6M DB), followed by a treatment extension period of up to 54 months in which all patients received lumasiran. Eligible patients were aged ≥6 years with genetically confirmed PH1, eGFR ≥30 ml/min per 1.73 m 2 , and mean 24-hour urinary oxalate (UOx) excretion ≥0.70 mmol/24 h per 1.73 m 2 . Results Of 39 patients enrolled, 24 of 26 randomized to lumasiran in the 6M DB (lumasiran/lumasiran group) and 13 of 13 randomized to placebo in the 6M DB (placebo/lumasiran group) completed the study. Sustained reductions in 24-hour UOx were observed in both treatment groups. At month 60 relative to study baseline, the mean (SEM) 24-hour UOx percentage reductions were 54 (6) and 54% (8%) in the lumasiran/lumasiran and placebo/lumasiran groups, respectively, and the mean (SEM) plasma oxalate concentrations had decreased by 35 (5) and 38% (7%). eGFR remained stable through the end of the study in both treatment groups. Kidney stone event rates during the study were 0.47 (95% confidence interval, 0.36 to 0.62) and 0.54 (0.37 to 0.78) per patient-year in the lumasiran/lumasiran group and placebo/lumasiran group, respectively. Medullary nephrocalcinosis grade improved at the end of the study in 21 of 28 (75%) patients with nephrocalcinosis at baseline and an end of study assessment. The safety profile of lumasiran was acceptable. Injection site reactions were the most common adverse events during lumasiran treatment. Most adverse events were mild or moderate in severity. Conclusions Lumasiran treatment for up to 60 months in ILLUMINATE-A was associated with sustained reductions in UOx excretion and plasma oxalate concentration, encouraging clinical outcomes including stable eGFR in a population that would be expected to show eGFR decline, reduced kidney stone event rates, improved medullary nephrocalcinosis, and indications of improved health-related quality of life. Clinical Trial registry name and registration number: ClinicalTrials.gov NCT03681184. Podcast This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2026_03_18_CJASNMar.21.3.31820.mp3

Abstract Quantifying urine protein is critical for detecting and monitoring kidney disease. However, screens for proteinuria are unable to detect low levels of albuminuria. For this reason, our institution has long measured urinary total protein and osmolality on routine urinalysis specimens (RUS) and calculated a predicted 24-hour protein excretion (PER) based upon the protein to osmolality ratio (POR). Within the last decade, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been approved by the United States Food and Drug Administration (FDA) as a treatment for adults with type 2 diabetes mellitus, and these agents appear to be beneficial for many forms of proteinuric renal disease and confer renal protection. Therefore, we investigated whether the expected glucosuria and increase in urine osmolality while on SGLT2i would significantly alter the POR, and hence predicted PER, via a retrospective analysis of residual timed and randomly collected urine specimens. Between January 1st, 2014, until January 29th, 2025, 5820 patients with nearly contemporaneous (collected within one week of each other) timed collections and RUS were identified that included 5656 not on SGLT2i (Cohort A) and 164 patients prescribed SGLT2i (Cohort B). Total protein concentrations were assessed using a Roche Cobas c701 by using benzethonium chloride. The osmolality was determined via freezing point depression using a Precision Systems Inc Multi-OSMETTE, whereas glucose measurements were made using either an Arkray AX-4030 with AUTION Stick 9EB test strips or a Clinitek Status with Multistix 10 SG reagent strips. Predicted 24-hour protein results were then calculated from the POR using a published formula based upon prior clinical studies: 10(x·[log(protein/osmolality)]+y where x is 0.908 or 0.953 for males and females, respectively, and y is 2.8254 or 2.9739 for males and females, respectively. In Cohort A, there was good correlation between the predicted and measured 24-hour PER (Spearman correlation coefficient, ρ = 0.78), although the predicted PER underestimated the measured PER (Passing-Bablok regression, y = 1.54x-20.97 mg/24 hr). Importantly, a strong correlation (ρ = 0.93) and similar distribution (p=0.17) were found between the predicted and measured PER in Cohort B, with a much-reduced proportional bias (y = 1.06x+62.96 mg/24 hr). Furthermore, comparison of the difference between the predicted and measured PER between the two cohorts demonstrated the same prediction accuracy (p = 0.65), with a median difference (interquartile range) of 79 mg/24 hr (256) and 109 mg/24 hr (480) for Cohort A and B, respectively. Finally, a strong correlation (ρ = 0.85), similar distribution (p = 0.23), and little bias (y = 0.96x+28.14 mg/24 hr) existed between the predicted and measured PER for all patients with overt glucosuria (urine glucose ≥1000 mg/dL, n = 348). In summary, these data suggest that the established formula for predicted PER on RUS is equally valid for patients on or off SGLT2i, and that this result is a useful clinical estimating tool.